TY - JOUR
T1 - A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
AU - Sheremata, William A.
AU - Vollmer, T. L.
AU - Stone, L. A.
AU - Willmer-Hulme, A. J.
AU - Koller, M.
PY - 1999/3/23
Y1 - 1999/3/23
N2 - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
AB - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
UR - http://www.scopus.com/inward/record.url?scp=0033596831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033596831&partnerID=8YFLogxK
U2 - 10.1212/wnl.52.5.1072
DO - 10.1212/wnl.52.5.1072
M3 - Article
C2 - 10102433
AN - SCOPUS:0033596831
VL - 52
SP - 1072
EP - 1074
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 5
ER -